Expanded Access to Telisotuzumab Vedotin
Latest Information Update: 31 Jul 2023
At a glance
- Drugs Telisotuzumab vedotin (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
- 07 Apr 2021 New trial record